5/3/24 5/3/24

The Impact of Billing Fraud on Patients and Their Health Insurance

Read More

5/3/24 5/3/24

The Impact of Incorrect Billing on Genetic and Molecular Testing Results

Read More

5/3/24 5/3/24

Managing Discrepancies in Reimbursement in Diagnostic Labs

Read More

5/3/24 5/3/24

Monetary Impact on Providers When Payors Recoup COVID Testing Claims During Public Health Emergency (PHE)

Read More

5/3/24 5/3/24

The Impact of Revisions in the 2018 Medicare Physician Fee Schedule on Clinical Diagnostic Labs

Read More

5/3/24 5/3/24

The Importance Of Having Dedicated Personnel For Tracking Payer Performance In Clinical Diagnostics Labs

Read More

5/3/24 5/3/24

How the No Surprises Act Could Impact Insurance Premiums for Diagnostic Lab Coverage

Read More

5/3/24 5/3/24

Can The 2022 Medicare Fee Schedule Cause A Delay In Diagnostic Process In Pathology Labs

Read More

5/3/24 5/3/24

Can Personal Protective Equipment Be Reimbursed Under The HRSA Uninsured Program

Read More

5/3/24 5/3/24

Can Laboratories Directly Bill Medicare for Molecular Testing?

Read More

5/3/24 5/3/24

Can Every Test Facility Offer Antibody Testing Reimbursement?

Read More

5/3/24 5/3/24

Recouping COVID Testing Claims from Private or Public Payors During the PHE

Read More

5/3/24 5/3/24

The Impact of Changes in Insurance Billing on the Reliability of Clinical Diagnostic Lab Results

Read More

5/3/24 5/3/24

Can Ai Completely Automate The Process Of Denial Management In Clinical Diagnostics?

Read More

5/3/24 5/3/24

Penalties for Not Complying with the No Surprises Act in Clinical Diagnostic Labs

Read More

5/3/24 5/3/24

Regulatory Implications for Cigna: Analyzing the Recent Decision

Read More

5/3/24 5/3/24

Penalties Associated With Overpayments Identified in the Bcbs Alabama Lab Overpayment Review

Read More

5/3/24 5/3/24

The Impact of Multiple Denied Payments for Ihcs from Medicare: Understanding penalties for Labs

Read More